AFP-464: Phase II started

Tigris began an open-label, U.S. Phase II trial to evaluate 74 mg/m 2 IV AFP-464 on days 1 and 8 of a 21-day cycle with and without Faslodex fulvestrant in about 50 estrogen receptor-positive breast ...